Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus

Thrombosis Research

Volumn 124, Issue 1, 2009, Pages 127-131

  Nojima, Junzo ^a   Iwatani, Yoshinori ^b   Ichihara, Kiyoshi ^a   Tsuneoka, Hidehiro ^a   Ishikawa, Toshizo ^a   Yanagihara, Masashi ^a   Takano, Toru ^c   Hidaka, Yoh ^c  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acquired activated protein C resistance; Anti phospholipid antibodies; Anti protein S antibodies; Lupus anticoagulant; Systemic lupus erythematosus

Indexed keywords

ACTIVATED PROTEIN C; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LUPUS ANTICOAGULANT; PROTEIN S;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FACTOR V; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; ODDS RATIO; PROTEIN S; RISK FACTORS; THROMBOEMBOLISM;

EID: 64649104433     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.11.006     Document Type: Article

References (23)

1. Lane D.A., Mannucci P.M., Bauer K.A., Bertina R.M., Bochkov N.P., Boulyjenkov V., et al. Inherited thrombophilia: Part 1. Thromb Haemost 76 (1996) 651-652
2. Dahlback B., Carlsson M., and Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 90 (1993) 1004-1008
3. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
4. Greengard J.S., Sun X., Xu X., Fernandez J.A., Griffin J.H., and Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 343 (1994) 1361-1362
5. Voorberg J., Roelse J., Koopman R., Buller H., Berends F., ten Cate J.W., et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 343 (1994) 1535-1536
6. De Stefano V., Martinelli I., Mannucci P.M., Paciaroni K., Chiusolo P., Casorelli I., et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341 (1999) 801-806
7. Martinelli I., Bucciarelli P., Margaglione M., De Stefano V., Castaman G., and Mannucci P.M. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 111 (2000) 1223-1229
8. Male C., Mitchell L., Julian J., Vegh P., Joshua P., Adams M., et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 97 (2001) 844-849
9. Nojima J., Kuratsune H., Suehisa E., Kawasaki T., Machii T., Kitani T., et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 118 (2002) 577-583
10. Haim N., Lanir N., Hoffman R., Haim A., Tsalik M., and Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 110 (2001) 91-96
11. Cumming A.M., Tait R.C., Fildes S., Yoong A., Keeney S., and Hay C.R. Development of resistance to activated protein C during pregnancy. Br J Haematol 90 (1995) 725-727
12. Rosing J., Tans G., Nicolaes G.A., Thomassen M.C., van Oerle R., van der Ploeg P.M., et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 97 (1997) 233-238
13. Galli M., and Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 93 (1999) 2149-2157
14. Oosting J.D., Derksen R.H., Bobbink I.W., Hackeng T.M., Bouma B.N., and de Groot P.G. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 81 (1993) 2618-2625
15. Roubey R.A. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 84 (1994) 2854-2867
16. Atsumi T., Ieko M., Bertolaccini M.L., Ichikawa K., Tsutsumi A., Matsuura E., et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 43 (2000) 1982-1993
17. Nojima J., Iwatani Y., Suehisa E., Kuratsune H., and Kanakura Y. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica 91 (2006) 699-702
18. Nojima J., Kuratsune H., Suehisa E., Kitani T., Iwatani Y., and Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies-Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 91 (2004) 967-976
19. Nojima J., Kuratsune H., Suehisa E., Iwatani Y., and Kanakura Y. Acquired Activated Protein C Resistance Associated with IgG Antibodies against β2-Glycoprotein I and Prothrombin as a Strong Risk Factor for Venous Thromboembolism. Clin Chem 51 (2005) 545-552
20. Nojima J., Kuratsune H., Suehisa E., Futsukaichi Y., Yamanishi H., Machii T., et al. Association between the prevalence of antibodies to β2-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 47 (2001) 1008-1015
21. Song K.S., Park Y.S., and Kim H.K. Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 43 (2000) 557-560
22. Merrill J.T., Zhang H.W., Shen C., Butman B.T., Jeffries E.P., Lahita R.G., et al. Enhancement of protein S anticoagulant function by β2-glycoprotein I, a major target antigen of antiphospholipid antibodies: β2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 81 (1999) 748-757
23. Bertolaccini M.L., Sanna G., Ralhan S., Gennari L.C., Merrill J.T., Khamashta M.A., et al. Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance. Thromb Haemost 90 (2003) 636-641